Assess whether pediatric studies are necessary or waivable (5985ab)

Situation

The desk packet is complete-response-letter deficiency list after a boxed-warning proposal from the review division. Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Pediatric studies are necessary / Waivable using complete-response-letter deficiency list after a boxed-warning proposal from the review division.

Hypotheses to test

• Pediatric-plan strategist can defend Pediatric studies are necessary from complete-response-letter deficiency list after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Pediatric-plan strategist cannot defend Pediatric studies are necessary from complete-response-letter deficiency list; Waivable is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in complete-response-letter deficiency list — reopen intake, do not close pediatric studies are necessary.
• Two facts in complete-response-letter deficiency list after a boxed-warning proposal from the review division conflict for pediatric-plan strategist; hold this Clinical and Evidence Strategy file.

Analysis required

• Check whether complete-response-letter deficiency list supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a boxed-warning proposal from the review division.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against a boxed-warning proposal from the review division and write the one fact that would move pediatric studies are necessary for pediatric-plan strategist.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.